Name | TMP920 |
---|
Description | TMP920 is a highly potent and selective RORγt antagonist. TMP920 inhibits RORγt binding to the SRC1 peptide with an IC50 of 0.03 μM[1]. |
---|---|
Related Catalog | |
Target |
IC50: 0.03 μM (RORγt)[1] |
In Vitro | TMP920 (0.09-30 μM) starts to show toxic effects on cell growth at >10 μM in Naïve CD4+ T cells[1]. TMP920 suppresses Th17 cell differentiation and lost its IL-17 inhibitory effect at <2.5 μM in vitro[1]. TMP920 suppresses IL-17 production from differentiated Th17 cells in vitro[1]. TMP920 suppresses the Th17 cell transcriptome and promotes alternate T-cell subsets[1]. TMP920 significantly reduces RORγt-DNA interactions[1]. Cell Cytotoxicity Assay[1] Cell Line: Naïve CD4 + T cells Concentration: 0.09-30 μM Incubation Time: 48 hours Result: Has toxic effects on cell growth at >10 μM. |
References |
Molecular Formula | C29H30N2O3 |
---|---|
Molecular Weight | 454.56 |